Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Sanofi","sponsor":"UK government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi\/GSK Sign Deal with UK Gov for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Sanofi","sponsor":"U.S Department of Health and Human Services","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK Land $2.1 Billion Deal With U.S. For Covid-19 Vaccine Development And 100 Million Doses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Sanofi","sponsor":"European Union","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi, Glaxosmithkline in Talks with EU to Secure Covid-19 Vaccine Deal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK Initiate Phase 1\/2 Clinical Trial of Covid-19 Adjuvanted Recombinant Protein-Based Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Sanofi","sponsor":"European Union","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK Will Provide Up To 300 Million Doses of COVID-19 Vaccine to the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Sanofi","sponsor":"Gavi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK to Support COVAX with 200 Million Doses of Adjuvanted, Recombinant Protein-Based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK Delay Their Adjuvanted Recombinant Protein-Based Covid-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Initiates Phase 1\/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Valneva"},{"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Translate Bio initiate Phase 1\/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Seppic","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akston Biosciences Announces Commercial Supply Agreement of Seppic\u2019s Adjuvant to Formulate Akston COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Seppic"},{"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$3,200.0 million","upfrontCash":"$3,200.0 million","newsHeadline":"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology Across Vaccines and Therapeutics Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$3,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Sanofi"},{"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Provides Regulatory Update on its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Valneva"},{"company":"EUROAPI","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CDMO: EUROAPI Supports Sanofi\u2019s mRNA Vaccine Platform with The Development of Lipid Nanoparticles","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"EUROAPI"}]

EUROAPI

Contact Supplier

EUROAPI, The leading small molecules API player covers both API Sales & CDMO.

Contact Supplier

Contact Supplier

Digital Content

CDMO: EUROAPI Supports Sanofi’s mRNA Vaccine Platform with The Development of Lipid Nanoparticles

Details:

EUROAPI will focus on lipids that are currently being tested as part of Phase I/II clinical trials that will support Sanofi’s mRNA vaccines platform, targeting indications including Flu.

Lead Product(s): mRNA Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Sanofi

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 30, 2022

EUROAPI Compnay Banner

BIO-Europe 2022

Booth # 72

envelop Contact Supplier

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Details:

Sanofi completed its acquisition of Translate Bio through the merger of a wholly owned subsidiary of Sanofi with and into Translate Bio which also allow to develop mRNA vaccines, MRT5500 and future infectious diseases.

Lead Product(s): SARS-CoV-2 mRNA Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: MRT5500

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Sanofi

Deal Size: $3,200.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition September 14, 2021

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology Across Vaccines and Therapeutics Development

Details:

The acquisition accelerates development of current sanofi licensed programs in vaccines, MRT5500 and potential to explore other therapeutic Areas, fast tracks establishment of sanofi’s recently announced mRNA center of excellence and business development.

Lead Product(s): SARS-CoV-2 mRNA Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: MRT5500

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Sanofi

Deal Size: $3,200.0 million Upfront Cash: $3,200.0 million

Deal Type: Acquisition August 03, 2021

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi and Translate Bio initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate

Details:

The Phase 1/2 clinical trial is a randomized, double blind and placebo-controlled trial designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of MRT5500, a COVID-19 vaccine candidate.

Lead Product(s): MRT5500

Therapeutic Area: Infections and Infectious Diseases Product Name: MRT5500

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 12, 2021

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi and GSK Delay Their Adjuvanted Recombinant Protein-Based Covid-19 Vaccine Program

Details:

In a phase I/II study of Sanofi/GSK’s adjuvanted recombinant protein-based vaccine, interim results found the vaccine induced an immune response comparable to recovered COVID-19 patients in adults aged 18 to 49 years.

Lead Product(s): Adjuvanted recombinant protein-based COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: GSK

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 11, 2020

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi and GSK to Support COVAX with 200 Million Doses of Adjuvanted, Recombinant Protein-Based COVID-19 Vaccine

Details:

Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities and subject to contract, to the COVAX Facility.

Lead Product(s): Adjuvanted COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Gavi

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 28, 2020

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi and GSK Will Provide Up To 300 Million Doses of COVID-19 Vaccine to the European Union

Details:

Agreement supports scale-up of manufacturing capabilities in several European countries . The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.

Lead Product(s): Adjuvanted COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: European Union

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 18, 2020

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi and GSK Initiate Phase 1/2 Clinical Trial of Covid-19 Adjuvanted Recombinant Protein-Based Vaccine Candidate

Details:

The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.

Lead Product(s): Adjuvanted COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: GSK

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi and GSK Land $2.1 Billion Deal With U.S. For Covid-19 Vaccine Development And 100 Million Doses

Details:

Collaborating with the U.S. Department of Health and Human Services and Department of Defense will help fund the development activities and secure scale-up of Sanofi’s and GSK’s manufacturing capabilities in the U.S for the recombinant protein-based, adjuvanted vaccine.

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: U.S Department of Health and Human Services

Deal Size: $2,100.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration July 31, 2020

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi, Glaxosmithkline in Talks with EU to Secure Covid-19 Vaccine Deal

Details:

The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: European Union

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 31, 2020

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

1
2

POST ENQUIRY